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Abstract The gene encoding the minibrain kinase/dual-
speciWcity tyrosine phosphorylated and regulated kinase 1A
(DYRK1A) is located in the Down syndrome (DS) critical
region of chromosome 21. The third copy of DYRK1A is
believed to contribute to abnormal brain development in
patients with DS. In vitro studies showing that DYRK1A
phosphorylates tau protein suggest that this kinase is also
involved in tau protein phosphorylation in the human brain
and contributes to neuroWbrillary degeneration, and that this
contribution might be enhanced in patients with DS. To
explore this hypothesis, the brain tissue from 57 subjects
including 16 control subjects, 21 patients with DS, and
20 patients with sporadic Alzheimer’s disease (AD) was
examined with two antibodies to the amino-terminus of
DYRK1A (7F3 and G-19), as well as two polyclonal anti-
bodies to its carboxy-terminus (X1079 and 324446). West-
ern blots demonstrated higher levels of full-length
DYRK1A in the brains of patients with DS when compared
to control brains. Immunocytochemistry revealed that
DYRK1A accumulates in neuroWbrillary tangles (NFTs) in
subjects with sporadic AD and in subjects with DS/AD.
Overexpression of DYRK1A in patients with DS was
associated with an increase in DYRK1A-positive NFTs
in a gene dosage-dependent manner. Results support the
hypothesis that overexpressed DYRK1A contributes to
neuroWbrillary degeneration in DS more signiWcantly than
in subjects with two copies of the DYRK1A gene and
sporadic AD. Immunoreactivity with antibodies against
DYRK1A not only in NFTs but also in granules in granulo-
vacuolar degeneration and in corpora amylacea suggests
that DYRK1A is involved in all three forms of degenera-
tion and that overexpression of this kinase may contribute
to the early onset of these pathologies in DS.
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Introduction
A broad spectrum of developmental and age-associated
changes in patients with Down syndrome (DS) is consid-
ered to be a result of the overexpression of genes localized
in the DS critical region of chromosome 21. The extra copy
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located on chromosome 21 appears to be the main cause of
the early onset of brain amyloidosis- in patients with DS.
Overexpression of APP has been associated with an
increase in amyloid  (A) 42 level in the brain of fetuses
with trisomy of chromosome 21 [64], the development of
diVuse A-positive plaques in approximately 50% of indi-
viduals with DS younger than 30 years of age [35, 37, 72,
73], Alzheimer-type pathology in the majority of DS sub-
jects older than 40 years of age [55, 69, 73], and an elevated
risk of Alzheimer’s disease (AD)-associated dementia [24,
33, 41, 78].
While early brain amyloidosis- appears to be directly
associated with an extra copy of the APP gene, the mecha-
nism leading to neuroWbrillary degeneration in patients
with DS is unknown. Recent studies suggest that the Mini-
brain kinase/dual-speciWcity tyrosine phosphorylated and
regulated kinase 1A (DYRK1A) gene, located in the critical
region of chromosome 21 [20, 50, 62] and overexpressed in
DS [21, 27], may play a signiWcant role not only in devel-
opmental brain defects associated with DS [46, 59] but
also in neuroWbrillary degeneration. The discovery that
DYRK1A phosphorylates microtubule-associated protein
tau at several phosphorylation sites and in cultured cells
[40, 74] implicates DYRK1A in abnormal tau phosphoryla-
tion and neuroWbrillary degeneration in patients with AD.
The observation that Thr212 is phosphorylated in fetal tau
and hyperphosphorylated in Wlamentous tau from subjects
with AD [43] supports this hypothesis. Moreover, phos-
phorylation of Thr212 by DYRK1A stimulates in vitro the
rate of phosphorylation of tau about eightfold through
priming tau phosphorylation by glycogen synthase kinase 3
(GSK3) at Ser208 [74]. Phosphorylation of Ser208 has also
been reported in tau in patients with AD [43]. DYRK1A-
induced tau phosphorylation inhibits tau activity to stimu-
late microtubule assembly and promotes its self-assembly
into Wlaments [40]. These Wndings strengthen the position
that DYRK1A may be involved in tau protein phosphoryla-
tion in the human brain and potentially in neuroWbrillary
degeneration.
The aim of this study was to explore the hypothesis that
DYRK1A contributes to neuroWbrillary degeneration in
patients with sporadic AD and that this contribution is
enhanced in DS subjects with trisomy of chromosome
21 and AD. Western blots demonstrated higher levels
of DYRK1A in the brains of patients with DS, whereas
immunocytochemistry with antibodies to DYRK1A
showed the presence of this kinase in neuroWbrillary tan-
gles (NFTs) in patients with sporadic AD. A several-fold
increase in the number of DYRK1A-positive NFTs in
patients with DS/AD supports the hypothesis that
DYRK1A contributes to the early onset of neuroWbrillary
degeneration in DS.
Materials and methods
Tissue for morphological studies
Brains of 57 subjects were examined, including 16 control
subjects 32–92 years of age (12 males and 4 females), 21
subjects with DS from 38 to 72 years of age (12 males and
9 females), and 20 subjects with sporadic AD 73–97 years
of age (11 males and 9 females). Functional assessment
staging (FAST) [51] was used to evaluate the progression
of the clinical course of sporadic AD. Control subjects were
classiWed as FAST stages 1 and 2 (normal adult without
functional decrement documented in available medical
records, and normal aged adult with subjective deWcit in
word Wnding, respectively). At the time of their demise,
three AD subjects were at FAST stage 3 (incipient AD with
deWcits noted in demanding employment settings); three
subjects at FAST stage 4 (mild AD with deWcits in perfor-
mance of complex tasks of daily life); two subjects at FAST
stage 5 (moderate AD manifested with deWcient perfor-
mance in choosing proper attire); four subjects at FAST
stage 6 (moderately severe AD manifested with Wve sub-
stages, including decreased ability to dress properly, to han-
dle mechanics of bathing and toileting, and Wnally with
urinary and fecal incontinence), and eight subjects at FAST
stage 7 (severe AD with several substages, including incip-
ient averbalism, limitation of speech to a single word, and
loss of ambulation). Patients were examined by clinicians
in the Aging and Dementia Research Center at New York
University Medical Center.
Fixation, processing, embedding, and neuropathological 
evaluation
One brain hemisphere from each subject was cut into 1-cm-
thick frontal slabs. Diagnostic tissue samples were cut oV
and Wxed in formalin for routine neuropathological exami-
nation, while the majority of tissue was frozen at ¡80°C for
biochemistry. Neuropathological evaluation was based on
gross brain description and examination of 8-m-thick sec-
tions from 16 brain regions. Alzheimer-type pathology was
evaluated using criteria developed at a consensus confer-
ence organized by the National Institute on Aging and the
Reagan Institute of the National Alzheimer Disease Associ-
ation [44]. According to Braak and Braak criteria [5], all
control subjects younger than 42 years of age were free of
AD pathology. All older control subjects were aVected with
incipient neuroWbrillary degeneration corresponding to
Braak and Braak criteria limbic stage I. They were free of
amyloid plaques. AD subjects represented a broad spectrum
of neuropathological changes from Braak and Braak limbic
stage II to neocortical stage VI. In the examined cohort, all
subjects with DS older than 38 years of age were aVected123
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with neuritic plaques corresponding to Braak and Braak
II–VI.
The other hemisphere was Wxed in 10% buVered forma-
lin for 6 weeks to several months and then dissected into
1-cm-thick frontal slabs. The tissue blocks were dehydrated
in a graded series of ethanol: for 5 days, in 70% ethanol;
then 2 days in 80% ethanol; and Wnally, 1 week in 96% eth-
anol. Dehydrated tissue was inWltrated with polyethylene
glycol (PEG) 400 (Merck #807 485) for 6 days (two
changes of 3 days each at room temperature) and with PEG
1000 for another 6 days (two changes of 3 days each at
42°C). Slabs were embedded in fresh PEG 1000 [25] and
stored in +4°C. Tissue blocks were then cut at a tempera-
ture of 18°C into 50-m-thick serial sections. They were
stored in 70% ethyl alcohol at room temperature and used
for immunocytochemical and morphometric studies.
The methods applied to this study were approved by the
Institutional Review Board at the New York State Institute
for Basic Research in Developmental Disabilities. All brain
tissue samples were identiWed by case number and exam-
ined blind to clinical and demographic information.
Immunostaining
Serial sections stored in 70% ethyl alcohol were washed
with phosphate buVer solution (PBS) and immunostained
as free-Xoating sections. Several antibodies were used to
detect DYRK1A (Table 1), including two antibodies to the
amino-terminus of DYRK1A: monoclonal antibody (mAb)
7F3 (IBR) [70] and goat polyclonal antibody (pAb)
Dyrk1A G-19 (Santa Cruz Biotechnology Inc.). The car-
boxy-terminus of DYRK1A was detected with sheep pAbs
X1079 from Exalpha Biologicals and sheep antibody
324446 from Calbiochem. Abnormally phosphorylated tau
protein of NFTs was detected with mAb Tau-1. Tau-1 rec-
ognizes an epitope between amino acids 189 and 207 of the
human tau sequence [17]. To obtain optimum staining with
Tau-1, sections were dephosphorylated with alkaline phos-
phatase prior to the application of primary antibody [19]
(Sigma, Type VII-L, 400 g/ml in PBS, pH 7.4). A-posi-
tive plaques were immunodetected with mouse mAb 4G8
(NYS, IBR), which recognizes amino acids 17–24 of the
amyloid -peptide [29]. To enhance the immunoreactivity
of A, sections were treated with concentrated formic acid
[31].
The endogenous peroxidase in the sections was blocked
with 0.2% hydrogen peroxide in methanol. Non-speciWc
bindings were blocked with 10% fetal bovine serum in PBS
for 30 min. The antibodies were diluted in 10% fetal bovine
serum in PBS and were incubated with sections overnight
at 4°C. The sections were washed and treated for 30 min









































































































































































































































































































































































































































































































































































































































































































































































394 Acta Neuropathol (2008) 116:391–407biotinylated donkey anti-goat IgG antibody diluted 1:200.
The sections were treated with an extravidin peroxidase
conjugate (1:200) for 1 h, and the product of reaction was
visualized with diaminobenzidine (0.5 mg/ml with 1.5%
hydrogen peroxide in PBS). After immunostaining, the sec-
tions were lightly counterstained with cresyl violet.
To conWrm the speciWcity of the immunostaining, the
reaction was tested with antibodies not absorbed as well as
those absorbed with appropriate peptides. For absorption,
antibody at the dilution 1:50 or 1:75 (the dilution at which
consistently positive results are achieved on sections) was
combined with a Wvefold (by weight) excess of blocking
peptide. The mixture was incubated for 2 h at room temper-
ature (or overnight at 4°C) and used for immunocytochemi-
cal tests. The eVect of tau protein dephosphorylation was
examined on sections pretreated and those not treated with
alkaline phosphatase.
Co-localization of Mnb/Dyrk1A and NFTs by double 
immunoXuorescence
Fifty-m-thick brain sections were double-immunostained
for DYRK1A using pAb G19, and for NFTs, using mAb
Tau-1. Sections treated with alkaline phosphatase were
incubated with G19 antibody, followed by a secondary don-
key antiserum against goat IgG conjugated with biotin
(Amersham), and then streptAvidin-FITC (Vector). The
second primary antibody was mAb Tau-1. The reaction was
detected with antibody made in sheep: F(ab)2 fragments
against mouse IgG conjugated to Cy3 (Sigma). The absence
of cross-reactions was conWrmed as described earlier [15,
16]. Images were generated using a Nikon Eclipse E800
microscope and the Nikon PCM 2000 dual-laser scanning
confocal microscopy system and with the C-Imaging-SIM-
PLE32™ image analysis system (Compix Inc.).
Detection of DYRK1A using Western blotting
Frozen tissue samples from the cerebral frontal cortex of
Wve control subjects 31–71 years of age, 12 DS subjects
from 28 to 63 years of age, and four subjects with AD from
71 to 85 years of age were used for the detection of
DYRK1A using Western blotting. Tissue was mortar-
ground in liquid nitrogen. 0.1 g of powdered brain tissue
was lysed in 1 ml of 6 M guanidine chloride buVer (6 M
GuHCl, 10 mM NaH2PO4, 10 mM Tris, 20 mM imidazole,
pH 8) and sonicated. The protein concentration was deter-
mined by bicinchoninic acid assay (BCA) (Pierce Rock-
ford, IL, USA). The total amount of protein extracted
from each brain sample was calculated, and volumes corre-
sponding to 4 mg of protein were mixed with 50 l of
Ni-Sepharose High Performance (Amersham) slurry and incu-
bated for 2 h at 4°C with constant rotation. Ni-Sepharose
beads were then washed three times with 1 ml 8 M urea
buVer (8 M urea, 100 mM NaH2PO4, 10 mM Tris, pH 5.9)
for each wash. Elution was carried out by boiling for 2 min
in 50 l of 1£ tricine sample buVer (BioRad) with 50 mM
EDTA. Ten microliter of each eluate was electrophoresed
on 8% tricine SDS-polyacrylamide gel and transferred onto
PVDF membrane. The membranes were blocked in 5%
non-fat milk and incubated overnight with the appropriate
dilution of monoclonal 7F3 [70] and goat polyclonal G19
(Santa Cruz Biotech, Inc.) antibodies. After incubation
with alkaline phosphatase-conjugated secondary antibody
(Amersham), the membranes were developed by color reac-
tion using BCIP/NBT as a substrate. The immunoreactive
bands on digitalized images were densitometrically quanti-
Wed using the 1D Scan EX3.1 software program (Scanalytics
Corp., Rockville, MD, USA).
Morphometry
On consecutive sections from the brains of subjects with
DS/AD and sporadic AD, the numerical density (n/mm3) of
neurons stained with cresyl violet (CV), and of neurons
with NFTs immunostained with antibodies Tau-1 and G-19
was evaluated. NFTs were counted in the four layers of the
entorhinal cortex known to be aVected early and severely
with neuroWbrillary degeneration (transentorhinal/entorhi-
nal stage of neuroWbrillary degeneration) [5], including lay-
ers II (islands of stellate cells), III, V, and VI. Sectors CA1
and CA4 of the cornu Ammonis and the pyramidal layer in
the subiculum proper were selected as representative for the
limbic stage of neuroWbrillary degeneration. Neurons with
NFTs were counted in a frame of 0.0035 mm2 in the entorh-
inal cortex and in a frame of 0.007 mm2 in three subdivi-
sions of the hippocampal formation. The depth of the
examined dissector was 30 m. Based only on neurons con-
taining Tau-1-positive NFTs, the proportion of neurons
with G-19-positive NFTs was calculated. NFTs were
counted in three histological sections representing the fron-
tal, middle, and caudal portions of the entorhinal cortex and
hippocampal formation. Twenty-Wve test areas were evalu-
ated for each examined subregion at a Wnal magniWcation of
3,100£.
Results
All samples were subjected to partial puriWcation by immo-
bilized metal (Ni2+) ion aYnity chromatography (IMAC).
DYRK1A binds with high aYnity to nickel ions chelated to
sepharose matrix through the histidine-rich domain in the
C-terminal part of the molecule [20, 23]. The samples were
made out of pools of cerebral frontal cortex tissue of Wve
control, 12 DS, and four AD subjects. Figure 1 shows the123
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pool, developed with monoclonal 7F3 and polyclonal G19
antibodies, both directed against the N-terminus of
DYRK1A protein. In all three pools, 7F3 and G19 antibody
detected, with similar relative intensity, two closely spaced
bands with the approximate molecular weights of 97 and
94 kDa. Densitometrical quantiWcation of immunoreactive
bands revealed an enhancement of DYRK1A levels in the
DS pool by the factor of 1.47 and 1.9 for 7F3 and G19 anti-
body, respectively. When compared with control subjects,
the AD pool showed visibly less DYRK1A by both anti-
bodies. The data shown in Fig. 1 are part of our published
study [13] in which cases comprising each pool were tested
and evaluated individually. In the course of this study, we
measured the levels of DYRK1A in six brain structures and
found a statistically signiWcant (P < 0.05) increase in the
DS group. The overall increase calculated for all six struc-
tures was 1.43-fold, very close to the predicted gene dosage
value of 1.5.
Immunodetection of DYRK1A in neurons free 
of neuroWbrillary degeneration
Immunostaining with mAb 7F3 revealed Mnbk/Dyrk1A in
the nucleus and cytoplasm of neurons, including neuronal
processes and synapses. However, the reaction varied sub-
stantially, ranging from heavy granular staining in the cell
nucleus and cytoplasm to just traces or even a total lack of
reaction product. The immunoreactivity was neuron type-
and brain structure-speciWc. Cytoplasmic immunoreactivity
with mAb 7F3 in normal brain was characterized in our
previous article [70]. Antibodies to DYRK1A G-19,
X1076, and 324446 also immunolabeled neurons in the
brains of controls, patients with DS, and patients with
sporadic AD. Immunoreactivity was observed mainly in
the cell body, but some reactivity was present in apical
dendrites, especially in sections stained with mAb 7F3
(not shown) and pAb G-19 (Fig. 2a–c).
DYRK1A immunoreactivity in NFTs
Antibody Tau-1 to tau protein and three antibodies to
DYRK1A (G-19, X1079, and 324446) immunolabeled neu-
rons in diVerent stages of NFT formation (Fig. 2d–i). In the
early stage of neuroWbrillary degeneration, formation of
NFTs was associated with enlargement of the cell body and
deformation and displacement of the cell nucleus to the cell
periphery. In this stage, the entire cytoplasm, including
NFTs, showed weak to moderate immunoreactivity to
DYRK1A (Fig. 2d–f). The progression of changes was
associated with a more selective enhancement of reaction in
bundles of cytoplasmic Wbers with the morphology of NFTs
and the proximal portion of dendrites, including apical den-
drites of pyramidal neurons (Fig. 2g–i). In contrast to the
common and strong pAb G-19 immunoreactivity of intra-
neuronal NFTs, and the weaker immunoreactivity with pAbs
to the C-terminus of DYRK1A (X1079 and 324448), NFTs
released from dead neurons (ghost tangles) were always
immunonegative (Fig. 2j–l). Mab 7F3 did not detect intra-
cellular or extracellular NFTs (ghost tangles, Table 2).
Immunostaining with pAb G-19 revealed numerous
DYRK1A-positive NFTs in the entorhinal cortex, limbic
structures, and isocortex in subjects with DS, but many
fewer in patients with sporadic AD (Fig. 3).
The appearance of Tau-1 immunoreactive NFTs in
neuronal bodies was associated with the appearance of
Tau-1-positive deposits in dendrites (neuropil threads). The
increase in the number of Tau-1-positive neuronal bodies
was paralleled with an increase in the number of Tau-1-
immunopositive neuropil threads in DS/AD and sporadic
AD. However, in sections stained with antibodies G-19,
X1079, and 324448, immunolabeling of NFTs in cell bod-
ies was observed in the almost total absence of immunore-
action in neuropil threads for both groups (Fig. 3). The
increase in the number of DYRK1A-positive NFTs in per-
sons with DS and severe Alzheimer-type pathology was not
associated with an increase in the number of immunoposi-
tive neuropil threads.
Colocalization of abnormally phosphorylated tau 
and DYRK1A in NFTs
Intraneuronal co-localization of DYRK1A and NFTs was
conWrmed by double-immunoXuorescence and confocal
microscopy. For Tau-1-negative neurons, the staining for
DYRK1A was granular and the product of immunoreactivity
Fig. 1 Representative Western blot of Ni–aYnity puriWed Dyrk1A
from the pools of the cerebral frontal cortex tissue of control (CTR Wve
cases; 31–71 years), Down syndrome (DS 12 cases; 28–63 years), and
Alzheimer disease (AD four cases; 71–85 years) subjects. Mixing
equal amounts of powdered brain tissue from each case made pools,
which were then processed for Western blotting and densitometric
quantiWcation. Equal loads of two identical sets of samples were sepa-
rated on 8% tricine SDS-polyacrylamide gel and immunoblotted with
a 1:5,000 dilution of monoclonal 7F3 antibody at a 1:10,000 dilution
of polyclonal G19 antibody. The blot was developed by color reaction
using AP-conjugated secondary antibodies and BCIP/NBP substrate.
The density of immunoreactive bands on digitalized images was mea-
sured by the 1D Scan EX3.1 software program. The value of the
DS:CTR ratio was the mean § SD of three independent Western blots.
Densitometry of control and DS samples revealed an enhancement of
DYRK1A levels in the DS pool by a factor of 1.47 for 7F3, and 1.9 for
G19 antibody. Both antibodies revealed less DYRK1A in the AD pool
when compared to controls123
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body and cell nucleus (Fig. 4a; and higher magniWcation,
Fig. 4aa). In some neurons, the accumulation of abnormally
phosphorylated tau in the early stage of neuroWbrillary degen-
eration (pretangle stage) was associated with the formation of
numerous Tau-1-immunopositive cytoplasmic granules in the
cell body and dendritic tree (Fig. 4b, bb). Some Tau-1-posi-
tive deposits were co-localized with G-19-immunoXuorescent
Fig. 2 Antibodies to the N-ter-
minal (G-19) and the C-terminal 
portion (X1079 and 324446) of 
DYRK1A reveal immunoposi-
tive material in the cytoplasm in 
neurons in CA1 (a), the nucleus 
basalis of Meynert (b), and CA4 
(c) in a 31-year-old control sub-
ject (arrowheads). Early stage of 
neuroWbrillary degeneration was 
associated with an increase in 
the size of neuronal body Wlled 
with G-19-, X1079-, and 
324446-positive NFTs; dis-
placement of the nucleus to the 
cell periphery; and diVuse cyto-
plasmic immunoreactivity in cell 
cytoplasm (arrowheads CA4 
sector in a 52-year-old subject 
with DS/AD; d–f). In the ad-
vanced stage of NFT formation, 
immunopositive material marks 
mainly bundles of NFTs (arrow-
heads CA1 sector in a 52-year-
old subject with DS/AD: g–i). 
However, ghost tangles (arrows) 
are immunonegative when 
stained with these three antibod-
ies (CA1 sector in a 52-year-old 
subject with DS/AD; j–l). 
MagniWcation: a £390; 
b–l £690123
Acta Neuropathol (2008) 116:391–407 397material, but some were not (Fig. 4c, cc). In spite of the strong
immunoreactivity of DYRK1A in both the cell body and pro-
cesses, co-localization of Tau-1- and G-19-positive material
was limited almost exclusively to the cell body. The progres-
sion of neuroWbrillary changes was reXected in an increase in
the amount of Tau-1-positive material and the formation of
bundles of NFTs immunoreactive only with Tau-1 or both
Tau-1 and G-19 (Fig. 4d–f). In some neurons, the portion of
bundles of NFTs was immunoreactive with Tau-1 or G-19
only, or with both antibodies (Fig. 4g–i). Tau-1-positive neu-
ropil threads were almost always G-19-negative. In contrast to
the uniform distribution of a Wne granular product of reaction
with pAb G-19 observed in normal neurons, G-19-immuno-
positive material formed several clusters of rough granules in
astrocytes (Fig. 4d, f).
DYRK1A-immunoreactive NFTs in morphometric study
Figure 5 illustrates the result of the immunocytochemistry-
based quantitative evaluation of G-19-positive NFTs in
subjects with DS/AD and sporadic AD. In subjects with
sporadic AD, the percentage of G-19-positive NFTs was
structure-speciWc: 10%, 16%, and 14% in layers II, III, and
V in the entorhinal cortex, respectively; 24% in the pyrami-
dal layer in the CA1 sector; but only 7% in the CA4 sector
and 12% in the pyramidal layer of the subiculum proper. In
subjects with DS/AD, the numerical density of G-19-posi-
tive NFTs in entorhinal cortex layers II, III, and V was
increased by about 3.7£, 2.0£, and 3.0£, respectively. In
the CA1 and CA4 sectors, their numbers were 1.5£ and
3.6£ higher, respectively, and in the subiculum, the num-
ber was increased by 2.6£.
Neuronal loss and neuroWbrillary degeneration in the
second layer of the entorhinal cortex (EC) of subjects with
DS/AD and sporadic AD is illustrated in Fig. 6. The similar
age at the onset of AD pathology in almost all DS subjects
results in the rather uniform neuronal loss in the second
layer of the EC of DS subjects and the correlation between
the numerical density of CV-positive neurons and age
(r = 0.75). The neuronal loss is paralleled by a decrease in
the numerical density of Tau-1-positive NFTs (r = 0.65).
The immunoreactivity of NFTs with G19 in all DS
subjects, including the youngest in the examined cohort
(38 years), suggests that DYRK1A contributes to the early
onset of neuroWbrillary degeneration in DS subjects. The
increase in the percentage of G19-positive NFTs (consider-
ing Tau-1-positive neurons as 100%) with age (r = 0.51)
suggests that DYRK1A contribution to neuroWbrillary
degeneration in DS increases with age. In three DS sub-
jects, 58, 63, and 67 years, almost all tau-positive NFTs
were G19-positive.
In the AD cohort, the numerical density of CV-posi-
tive neurons in the second layer of the EC decreases
from 30,000–40,000 mm¡3 in the early stages to about
15,000 in the late stages (Fig. 7b–f). In contrast to DS,
sporadic AD starts at a diVerent age, and the correlation
between the number of neurons and age is not signiWcant
(r = 0.29), but the number of neurons correlates with
FAST stage (r = ¡0.87). The decrease in the numerical
density of Tau-1-positive neurons correlates with the
stage of AD (r = ¡0.76), but not with age (r = 0.22). In
sporadic AD, G19-positive neurons represent a low per-
centage of Tau-1-positive NFTs. They were not found in
eight subjects with sporadic AD. In six subjects, the
Table 2 Immunoreactivity in neurons, glial cells, and corpora amylacea with antibodies to DYRK1A
NFTs neuroWbrillary tangles, GVD granulovacuolar degeneration
Structures Antibody
7F3 N-terminus G-19 N-terminus X1079 C-terminus 324446 C-terminus
Neuron
Nucleus +++ + + +
Cytoplasm +++ ++ ++ ++
NFTs ¡ ++++ ++ ++
Neuropil threads ¡ § § §
Ghost tangles ¡ ¡ ¡ ¡
Dystrophic processes in amyloid plaques + + + +
GVD (cores) ¡ ¡ ++ ++
Astrocyte
Nucleus ¡ ¡ ¡ ¡
Cytoplasm ++ ++ ++ ++
Microglia and oligodendrocytes
Nucleus, cytoplasm ¡ ¡ ¡ ¡
Corpora amylacea +++ ++ ++ ++123
398 Acta Neuropathol (2008) 116:391–407number was less than 10%. In only six AD subjects, it
varied from 25 to 67%. In contrast to DS, in sporadic
AD, in the later stages of disease (FAST stages 6 and 7),
the number of G19-positive NFTs was low, or they were
not found.
Dephosphorylation with alkaline phosphatase did not
change the pattern of DYRK1A distribution in NFTs (not
shown) in the brains of people diagnosed with DS/AD or
sporadic AD.
DYRK1A immunoreactivity in astrocytes
Two types of reaction were observed in astrocytes. In the
majority of the subjects with DS, almost all astrocytes
Fig. 3 In a 67-year-old subject 
with DS, the presence of numer-
ous Tau-1-immunoreactive 
NFTs in neuronal bodies and 
apical dendrites (arrows) is par-
alleled with the appearance of 
numerous Tau-1-immunoposi-
tive neuropil threads (arrow-
heads) in the amygdala (AMY), 
the second layer of the entorhi-
nal cortex (EC), and the pyrami-
dal layer in the cornu Ammonis 
(CA1). In a subject with sporadic 
AD and moderately severe clini-
cal pathology at the time of 
demise (FAST 6d), only a few 
NFTs (arrow) are G-19-positive. 
In contrast to Tau-1, which 
stains numerous neuropil 
threads, antibody G-19 does not 
detect neuropil threads. MagniW-
cation a–c £55, d–l £430123
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that were 7F3- and G-19-positive but Tau-1-negative.
Immunoreactivity with X1079 and 324448 was less consis-
tent and usually weaker than immunolabeling with 7F3 and
G19. In patients with sporadic AD, granular staining in
astrocytes was less pronounced, but astrocytes in the sube-
pendymal zone and in the molecular layer of allocortex and
isocortex often showed mild to strong diVuse staining both
in the astrocyte body and the processes. This pattern of
staining was especially common and strong in astrocytes
in neuritic plaque corona (Fig. 7a–c). Immunoreactivity
with 7F3, G-19, X1079, and 324448 was undetectable in
microglial cells and oligodendrocytes.
DYRK1A immunoreactivity in neuritic plaques
All subjects with DS/AD older than 38 years of age and all
patients with sporadic AD were aVected by amyloidosis,
with numerous neuritic plaques detected with mAb 4G8 in
both cortical and subcortical gray matter (not shown). In a
large proportion of the neuritic plaques detected with mAb
4G8, mAb Tau-1-labeled numerous swollen dystrophic
neuronal processes containing abnormally phosphorylated
tau. Mild/moderate reactions with G-19, X1079, and
324448 were observed in about 20% of these plaques in
areas corresponding to dystrophic neuronal processes
(Fig. 7d–f).
Fig. 4 Section from the cornu 
Ammonis of the 67-year-old DS 
subject immunostained with 
pAb G-19 (green color) and 
mAb Tau-1 (red color) and ana-
lyzed in confocal microscope. 
Fine-granular, evenly distributed 
immunoreactivity is detected 
with pAb G-19 in the body of 
two neurons marked with 
arrowheads (a, aa higher magni-
Wcation of one of these neurons). 
One neuron contains rough-
granular deposits of Tau-1-
positive material (arrow) 
corresponding to an early stage 
of neuroWbrillary degeneration 
(b, bb). Yellow color corre-
sponds to partial co-localization 
of the product of reaction for 
DYRK1A and abnormally phos-
phorylated tau protein (c, cc). 
d–f A normal neuron positive for 
DYRK1A and negative for 
Tau-1 (1); a neuron with NFT 
immunoreactive with Tau-1 only 
(2); and a neuron with NFT 
immunoreactive with both anti-
bodies (3; G-19, green; Tau-1, 
red; co-localization, yellow). 
The cytoplasm of astrocytes is 
Wlled with clusters of G-19-
positive rough granules (arrow-
heads). A neuron in the late 
stage of neuroWbrillary degener-
ation (g–i, arrowhead) contains 
some bundles of NFTs immuno-
reactive with both G-19 and 
Tau-1 (yellow). MagniWcation 
a–c and d–f £410, aa–cc 
£1,430, g–i £1,025123
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In subjects with DS/AD and sporadic AD, numerous neu-
rons in the pyramidal layer of the cornu Ammonis were
aVected with granulovacuolar degeneration (GVD). The
cell body contained several large vacuoles, each with a
dense core. The number of aVected neurons was increased
in the middle stages of AD pathology. However, in subjects
with severe AD, loss of neurons was associated with a
reduction in the number of neurons with GVD. In the cornu
Ammonis, immunostaining with C-terminal antibodies
X1079 and 324448 revealed moderate to strong reactions in
the cores in cytoplasmic vacuoles of neurons aVected with
GVD; however, reactions with N-terminal antibodies 7F3
and G-19 were undetectable (Fig. 7g–i).
Corpora amylacea were a common Wnding in control
subjects as well as in subjects with sporadic AD and
DS/AD. They were strongly immunopositive in sections
stained with 7F3 and moderately immunopositive in sec-
tions stained with G-19, X1079, and 324448 (Fig. 7j–l). A
strong reaction was present not only in large corpora amyl-
acea in the subpial, subependymal, and perivascular loca-
tion but also in tiny corpora amylacea dispersed in the
cortex and subcortical structures undetectable with CV.
Discussion
Recent studies indicate that DYRK1A is involved in sev-
eral molecular mechanisms leading to tau phosphorylation
and that overexpression of DYRK1A in patients with tri-
somy of chromosome 21 and DS may contribute to the
early onset of neuroWbrillary degeneration. DYRK1A is
present in the neuronal cytoplasm and nucleus [14, 70] and
has been reported to phosphorylate both cytoplasmic and
nuclear substrates [30, 40, 53, 74], suggesting that the sub-
cellular localization of the protein reXects the cytoplasmic
and nuclear pathway leading to neuroWbrillary degenera-
tion.
Cytoplasmic pathway
DYRK1A phosphorylates the human microtubule-associated
protein tau at Thr212 in vitro, a residue that is hyper-
phosphorylated in AD and tauopathies, including Pick
disease [14, 74], and permits phosphorylation of Ser208 by
glycogen synthase kinase 3 [74]. Ferrer et al. [14] observed
modiWcations in the expression of the constitutive cytoplas-
mic and nuclear DYRK1A in neurodegenerative diseases
associated with tau phosphorylation including DS, AD, and
Pick disease. However, they could not Wnd any evidence
that DYRK1A is directly involved in neuroWbrillary degen-
eration.
Application of two antibodies to the N-terminal portion
of DYRK1A, 7F3 [70] and G-19, and of two antibodies to
the C-terminal portion of DYRK1A, X1076 and 324446,
shows that the distribution of DYRK1A in the normal
human brain undergoes modiWcations associated with neu-
roWbrillary degeneration in DS/AD and sporadic AD. In
control brains, all four antibodies reveal immunoreactivity
in neurons, both in the cell body and the processes. A stron-
ger reaction is observed in sections stained with antibodies
to the N-terminal compared to the C-terminal portion of
DYRK1A. DYRK1A contains a nuclear targeting sequence
and is distantly related to the mitogen-activated protein
kinase family [27]. Intranuclear localization of DYRK1A
was shown in human neurons with mAb 7F3 [70], but three
antisera, including G-19, detect less immunoreactivity in
the cell nucleus.
Our study oVers evidence that DYRK1A is directly
involved in neuroWbrillary degeneration. Antiserum G-19
shows a strong reaction in the majority of NFTs in patients
with DS, and antisera X1079 and 324446 react with only
about 10% of G-19-positive NFTs.
On the other hand, mAb 7F3 does not react with NFTs.
The observed diVerences in immunoreactivity of NFTs
with antibodies and antisera against diVerent sequences of
DYRK1A suggest that epitopes detected by these antibod-
ies/antisera are masked in complexes of DYRK1A with tau
and other proteins in intracellular NFTs.
Nuclear substrates phosphorylated by DYRK1A
We documented that DYRK1A phosphorylates alternative
splicing factor (ASF) at three sites (unpublished data).
Fig. 5 Graph illustrates a several-fold higher percentage of G-19-pos-
itive NFTs (when the number of Tau-1-positive NFTs is considered
100%) in the entorhinal cortex (EC) layers II, III, and V, in the CA1 and
CA4, and in the subiculum proper (SUB) in the brains of persons with
DS compared to subjects with sporadic AD123
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ASF relocation to the nucleus, whereas phosphorylation by
Clk/Sty releases ASF from speckles [32, 45] and recruits it
into nascent transcripts, where ASF regulates alternative
splicing. Phosphorylation of nuclear ASF by DYRK1A
drives ASF back to speckles, decreases involvement in regu-
lation of alternative splicing, and inhibits ASF’s ability to
promote tau exon 10 inclusion. The result is an increase in
3R tau level and an imbalance of 3R/4R tau ratio. The
imbalance could be the factor initiating and accelerating
neuroWbrillary degeneration in the brain of patients with DS.
DYRK1A in NFTs
Co-localization of DYRK1A with NFTs, described in this
article and by in vitro studies showing tau protein
phosphorylation with DYRK1A priming tau phosphoryla-
tion with GSK-3, suggests that DYRK1A plays a role in
neuroWbrillary degeneration and that this process is much
more pronounced in neurons of patients with DS than in
patients with sporadic AD. In NFTs, tau protein is phos-
phorylated by several protein kinases, including GSK-3,
cyclin-dependent kinase 5 (cdk5), JNK, ERK1/2, and p38
at more than 30 phosphorylation sites [18, 22, 34, 42, 52,
60]. Several kinases in their activated forms co-localize
with NFTs in AD, including mitogen-activated protein
kinase (MAPK) [66], microtubule-aYnity regulating kinase
(MARK) [9], GSK-3 [36, 47, 48, 76], cdk 5 [76], cdc2-
related kinase [38], and casein kinase 1 (Cki) [57]. This
study shows that DYRK1A colocalizes with NFTs in all
subjects with DS/AD but in only 60% of subjects diagnosed
with sporadic AD.
Fig. 6 Graphs illustrate changes in the numerical density of neurons
stained with CV and NFTs immunoreactive with Tau-1 antibody and
G19-antibody detecting DYRK1A in NFTs in DS subjects (left col-
umn) and in AD (right column) in the second layer of the entorhinal
cortex. The early onset of neuroWbrillary degeneration results in neu-
ronal loss. In the DS cohort, the decrease in the numerical density
of CV-positive neurons and Tau-1-positive NFTs correlates with
age (r = ¡0.75 and ¡0.65, respectively; P < 0.05). DYRK1A-positive
NFTs (G19-immunoreactive NFTs) are present in the entorhinal cortex
of all DS subjects from 38 to 72 years. The percentage of DYRK1A-
positive NFTs (tangles immunoreactive with G19) increases with age
(r = 0.51; Tau-1-positive NFTs were considered as 100%). Also in the
AD cohort, a decrease in the numerical density of CV-positive and
Tau-1-positive NFTs strongly correlates with stage of disease (FAST;
r = ¡0.87, and r = ¡0.76, respectively). However, in contrast to the
DS cohort, 40% of subjects with sporadic AD do not have DYRK1A-
positive NFTs; in 30% of subjects, less than 10% of Tau-1-positive
NFTs are G-19-immunoreactive, and only 30% of subjects have from
25 to 67% of G19-immunoreactive NFTs. The majority of subjects
with severe sporadic AD (FAST 6 and 7) are free of DYRK1A-positive
NFTs123
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A gene dosage eVect has been proposed to explain the role
of an extra chromosome 21 in the pathology of DS. Studies
in fetuses with DS show reduced (HACS1) or unmodiWed
levels of some proteins (alpha A-crystalline, FTCD,
GARS-AIRS-GART, and CBS), including DYRK1A,
which are encoded by genes on chromosome 21. These data
Fig. 7 In a 67-year-old subject 
with DS, in some cored plaques, 
diVuse immunoreactivity with 
G-19, X1079, and 324446 
appears in the activated astro-
cyte body and processes (arrow-
heads, CA1 a–c). In about of 
20% of cored plaques, antibod-
ies to DYRK1A label dystrophic 
neuronal processes (arrows; 
d–f). In the CA1 sector, granules 
(arrowheads) in neurons with 
granulovacuolar degeneration 
are negative when stained with 
antibodies to the N-terminus of 
DYRK1A (7F3, not shown; 
G-19 shown in g) but positive 
when stained with X1079 and 
324446 (h, i). Strong immuno-
reactivity with all three antibodies 
appears in corpora amylacea 
(arrowheads) in the hippocampus 
(j and l dentate gyrus; k CA4). 
MagniWcation a–f £210, 
g–i £1,075, j–l £210123
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the formation of DS phenotype in utero [8].
However, in adults with DS, Western blots revealed an
almost 50% higher level of DYRK1A protein in extracts
from the frontal cortex. The study of other cortical regions
in the human cortex conWrmed a 50% increase in expres-
sion of this kinase linked to an extra copy of Dyrk1A gene
in subjects with trisomy of chromosome 21 and DS [13].
The presence of DYRK1A-positive NFTs in all subjects
with DS/AD but in only 60% in sporadic AD cases, and a
much higher percentage of NFTs in DS subjects than in
subjects with sporadic AD appears to reXect the overex-
pression of the DYRK1A gene and the link between the
excessive amount of this kinase and the onset and progres-
sion of neuroWbrillary degeneration. Overexpression of the
APP gene, increased concentrations of A in DS fetuses
[64], and the early onset of diVuse [35, 73] and Wbrillar A
deposits [73] represent additional evidence of the selective
overexpression of genes throughout the entire lifespan of
patients with DS.
DiVerences in NFTs’ immunoreactivity in DS/AD 
and sporadic AD
GSK3, cyclin-dependent kinase (cdk) 5 [76], and
DYRK1A were found in only some NFTs. These observa-
tions and the signiWcant diVerences in NFTs’ immunoreac-
tivity in patients with DS/AD and sporadic AD imply the
presence of multiple patterns of tau phosphorylation and
neuroWbrillary degeneration. Perhaps, the percentage of
NFTs that are positive to a given kinase is disease-, stage of
disease-, and brain structure-speciWc. The present observa-
tions may also suggest that patterns of tau phosphorylation
with DYRK1A in persons with DS are diVerent than those
in patients with sporadic AD. This diVerence may reXect a
variation in the progression of neuroWbrillary degeneration
and, possibly, neuronal loss. In spite of the presence of sig-
niWcant neuroWbrillary degeneration and amyloidosis- in
almost all patients with DS 40 years of age and older [72,
73], clinically signiWcant functional deterioration has not
been reported to increase in prevalence until some 10 years
later [24, 33, 76]. The prevalence of dementia in the DS
cohort is estimated as 55% in the age group of 50–59 years,
and 75% in subjects older than 60 years of age [33]. One
may hypothesize that tau phosphorylation and neuroWbril-
lary degeneration are modiWed in persons with DS/AD
when compared to sporadic AD. The presence of DYRK1A
in the NFTs of the youngest DS subjects with neuroWbril-
lary degeneration indicates DYRK1A’s contribution to the
early onset of NFTs in DS. A lower percentage of G-19-
positive NFTs in DS subjects before they reach 50 years of
age and a high percentage in subjects in their 50s or 60s
might be an indication of an enhanced contribution of
DYRK1A to tau phosphorylation and neuroWbrillary
degeneration in older patients with DS. The lack of immu-
noreactivity of NFTs with antiserum detecting DYRK1A
(G19) in 40% of AD subjects and the low percentage of
G19-positive NFTs in the other 30% of AD subjects reXect
the diVerence in contribution of overexpressed DYRK1A to
neuroWbrillary degeneration in DS/AD and the contribution
of normal level of DYRK1A in sporadic AD.
The study of chromosome 21 genetic associations with
late-onset AD revealed that the DYRK1A gene has the high-
est signiWcance as a genetic risk factor [30]. The dramatic
diVerence between DYRK1A’s role in neuroWbrillary degen-
eration in DS/AD and in sporadic AD appears to be the
product of several molecular mechanisms, including (a) the
cytoplasmic pathway with phosphorylation of tau by
DYRK1A and the priming of tau phosphorylation by GSK3b
[40, 78], (b) the nuclear pathway with phosphorylation of
ASF by DYRK1A and the imbalance between 3R and 4R tau
(unpublished data), as well as (c) phosphorylation of APP by
DYRK1A at Thr668 in vitro and in mammalian cells [54]. The
experiments showing that A loading in neuroblastoma cells
and transgenic mice increases expression of DYRK1A gene,
resulting in hyperphosphorylation of tau at Thr212, support the
hypothesis that DYRK1A could be a key molecule linking
-amyloid production with tau phosphorylation [30, 53, 54].
DYRK1A in neuropil threads and dystrophic neurites, 
but not in ghost tangles
A striking feature of the immunolabeling of neurons with
neuroWbrillary degeneration with antibodies to GSK-3,
MPM-2, and cdc2 is the positive reaction with PHFs in the
neuronal body but the only sparse reactivity with neuropil
threads and dystrophic neurites in the plaque perimeter [67,
76]. It was proposed that this diVerence might be attribut-
able to a diVerential sensitivity of neuritic components to
Wxation [38]. The strong immunostaining of NFTs observed
in the cell body in the majority of neurons with neuroWbril-
lary degeneration in older subjects with DS/AD, the
absence of immunoreactivity with antiserum G-19 in neu-
ronal processes (neuropil threads), and the sparse immuno-
reactivity observed in dystrophic neurites in cored plaque
corona may indicate that DYRK1A is involved in tau phos-
phorylation mainly in the cell body. These observations
may also suggest that the pattern of tau phosphorylation in
the cell body is diVerent from that in the dendrites, and that
G-19-positive complexes of abnormally phosphorylated tau
do not extend to dendrites. However, the possibility that the
lack of reaction with antibodies against DYRK1A in neuro-
Wbrillary threads in dendrites and synapses could be the
result of masking of epitopes in vivo or the loss of immuno-
reactivity postmortem including tissue processing cannot
be excluded at this phase of study.123
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MPM-2 was considered evidence that these kinases play a
role in the early stages of neuroWbrillary degeneration [67].
Transformation of intracellular NFTs into extracellular
ghost tangles is associated with the loss of epitopes recog-
nized by antibodies raised against the amino- and carboxy-
termini of tau [4]. Extracellular NFTs are immunonegative
not only to DYRK1A but also to GSK-3 [76]. The majority
of ghost tangles are also negative when stained with anti-
bodies against cdc2 and MPM-2 [67]. Proteolytic process-
ing with a loss of the N- and C-terminal portions of tau is
associated with the secondary deposition on NFTs of ubiq-
uitin [3, 63], of heparan sulfate proteoglycans [3], and, in
some brain regions, of A [4, 63, 71, 75]. The absence of
DYRK1A in ghost tangles indicates that this binding reX-
ects a contribution to neuroWbrillary degeneration rather
than unspeciWc adhesion to already formed NFTs.
Lack of DYRK1A in NFTs in aged control subjects
In general, the properties of NFTs in aged individuals with-
out dementia recapitulate those found in NFTs in AD [10].
In contrast to the accumulation of DYRK1A in about 50%
of NFTs in DS subjects and the much lower percentage of
NFTs in patients with sporadic AD, NFTs in control sub-
jects are free of DYRK1A. The lack of DYRK1A in NFTs
of aged controls is not due to the absence of this kinase,
because immunocytochemistry shows widespread distribu-
tion of DYRK1A in neurons. This pattern resembles the
accumulation of protein kinase M (PKM) in the NFTs of
subjects with AD but the absence in NFTs of aged control
subjects [10]. The observed NFT immunoreactivity indi-
cates that the association of kinases with NFTs is kinase-
speciWc and aging-, AD-, and AD/DS-speciWc.
DYRK1A in GVD and corpora amylacea
Granulovacuolar degeneration is observed in a small per-
centage of neurons in the majority of normal aged subjects,
and their number increases in persons with AD [65]. The
granular component of vacuoles reacts with antibodies to
tubulin [49] and antibodies to abnormally phosphorylated
tau [11], and GSK-3 [36, 76]. The presence of DYRK1A
immunoreactivity in granules in neurons with GVD
detected with C-terminal antibodies and the lack of reactiv-
ity with antibodies against the N-terminus may indicate that
only N-terminally truncated products of DYRK1A process-
ing contribute to GVD or selectively accumulate in these
granules.
Corpora amylacea are considered as a sign of the earliest
changes associated with aging and/or neurodegeneration in
neurons [6], including axons [1, 7] and synapses [2] as well
as glial cells, especially astrocytes [6, 12, 56, 61]. Strong
immunoreactivity with antibody 7F3 [70] and with antibod-
ies G-19, X1073, and 324446 suggests the involvement of
DYRK1A in this form of neuron and astrocyte degenera-
tion and the early onset of these changes in DS.
DYRK1A appears to be involved in many forms of neu-
ronal degeneration including Lewy bodies, a pathological
hallmark of Parkinson’s disease. DYRK1A phosphorylates
-synuclein at Ser87 and selectively binds to -synuclein
in transformed and primary neuronal cells. The fact that
aggregates formed by phosphorylated -synuclein are more
toxic when compared with aggregates composed of unmod-
iWed wild-type -synuclein, suggests that -synuclein inclu-
sion formation regulated by DYRK1A may aVect neuronal
cell viability [28].
Phosphorylation of tau protein by one kinase facilitates
or inhibits phosphorylation by other protein kinases in vitro
[26, 58, 68, 74, 77] and in vivo [39]. The reported Wndings
and other studies [40] suggest that kinases work in a
coordinated way and that overexpressed DYRK1A is a
major factor contributing to the DS-speciWc pattern of neuro-
degeneration. DYRK1A’s contribution to neuroWbrillary
degeneration in DS appears to be much more signiWcant
than in subjects with two copies of the DYRK1A gene and
sporadic AD. The presence of DYRK1A not only in NFTs
but also in granules in GVD and in corpora amylacea
suggests that DYRK1A is involved in all three forms of
degeneration and may contribute to the early onset of these
pathologies in DS.
Protein kinase A (PKA) might be involved in the abnor-
mal phosphorylation of tau in an upstream position to GSK-
3 and possibly other proline-directed protein kinases [39].
DYRK1A phosphorylates tau at several sites and facilitates
the phosphorylation of tau at several sites by GSK-3 [40,
74]. Whereas PKA is considered to be a potential therapeu-
tic target for the treatment of neuroWbrillary degeneration in
patients with sporadic AD [39], overexpressed DYRK1A
might be considered a major target for treatment of neuro-
nal degeneration in patients with DS/AD.
Western blots demonstrated increase of DYRK1A in the
DS group when compared to the control and AD group.
The presence of DYRK1A in NFTs in sporadic AD indi-
cates that DYRK1A contributes to tau phosphorylation
even in the absence of increased gene dosage. However, an
increase in DYRK1A-positive NFTs in a gene dosage-
dependent manner in subjects with DS, including the
youngest NFT-positive DS subjects, indicates that over-
expressed DYRK1A contributes to the early onset of
neuroWbrillary degeneration in DS. The correlation between
the percentage of G19-positive neurons and the age of DS
subjects suggests that the contribution of DYRK1A to neu-
roWbrillary degeneration increases in the later stages of AD
in the DS cohort. Immunoreactivity with antibodies against
DYRK1A in granules in GVD and in corpora amylacea123
Acta Neuropathol (2008) 116:391–407 405suggests that DYRK1A is involved in the early onset of all
three forms of degeneration in DS.
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